Silence Therapeutics website uses cookies. By continuing to browse you are agreeing to our use of cookies.
Channelling gene silencing to control disease.
Our executive leadership team is highly experienced in a variety of relevant sectors, from molecular biology and genetics to pharmaceutical development, BD deals and corporate finance.
Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value.
Silence Therapeutics strives to conduct its business in an ethical, responsible and transparent manner.
Our Board of Directors is formed by seven accomplished members, two Executive and five Non-Executive Directors.
We aim to stay in the frontline of the fast-moving field of oligonucleotide therapeutics. Our Scientific Advisory Board (SAB) is a group of world-leading experts in drug discovery and clinical development with particular expertise in the rare disease space. The SAB challenges us to excel at siRNA molecular design, drug discovery, and development
We offer a vibrant culture and environment where innovation and creativity is encouraged.
Download the Corporate Presentation here
Our technology is a highly specific and modular platform designed to inhibit or ‘silence’ the expression of disease-causing genes, allowing cells to revert to their healthy state.
We are committed to creating collaborations that maximise value for each of the partners.
We have established, maintained and actively pursue intellectual property protection for our technology.
Discover how our siRNA based therapies work
Effective siRNA delivery to the right cells is a challenge given the complexity of the human body. Discover how we aim to address this.
View our latest news, publications and videos here.
View our Latest News here.
Upcoming and past events.
View our Press Coverage here.
View our Publications here.
View our Marketing Materials here.
View our Videos here.
To support better understanding of our focus diseases, we have developed the following ‘eBooks’ to provide an overview of their impact and current management.
General resource to improve understanding of Myelodysplastic Syndromes (MDS)
General resource to improve understanding of elevated Lipoprotein(a) (Lp(a))
General resource to improve understanding of Thalassaemia
